Latest news with #EdgewiseTherapeutics
Associated Press
20-07-2025
- Business
- Associated Press
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Jul 19, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ('Edgewise' or 'the Company') (NASDAQ: EWTX ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Edgewise reported data from the clinical trials on its drug candidate sevasemten on June 26, 2025. The Company claimed the results were positive but also disclosed that the FDA had 'deemed the CANYON data alone insufficient for an accelerated approval.' Based on this news, shared of Edgewise fell by 8.86% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Schall Law Firm Copyright Business Wire 2025. PUB: 07/19/2025 06:58 PM/DISC: 07/19/2025 06:57 PM
Yahoo
05-07-2025
- Business
- Yahoo
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment
Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise Therapeutics announced positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. For Becker muscular dystrophy, the company reported positive data from MESA, which is an open-label extension trial that provides continued access to sevasemten for participants previously enrolled in ARCH, CANYON, GRAND CANYON, or DUNE trials. Sevasemten maintained a favorable safety profile over up to 3 years of treatment. For Duchenne muscular dystrophy, Edgewise announced encouraging topline data from its Phase 2 LYNX and FOX trials. A scientist in a lab coat using a microscope to study a cultured biopharmaceutical product. Sevasemten is an orally administered and first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies like Becker and Duchenne. Becker muscular dystrophy is a rare, genetic, debilitating, and degenerative neuromuscular disorder primarily affecting males, with no currently approved therapies. Duchenne muscular dystrophy is a severe degenerative muscle disorder, the most common type of muscular dystrophy, with a median life expectancy of around 30 years. Edgewise Therapeutics Inc. (NASDAQ:EWTX) is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders. While we acknowledge the potential of EWTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-06-2025
- Business
- Yahoo
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
Wedbush analyst Laura Chico lowered the firm's price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated filing for sevasemten in Becker muscular dystrophy, but the company will explore additional avenues to speed the process, and will seek full approval with GRAND CANYON, the analyst tells investors in a research note. Wedbush still sees several unanswered questions for sevasemten in DMD such as the patient population to be studied, the firm says. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on EWTX: Disclaimer & DisclosureReport an Issue Edgewise Therapeutics Announces Positive Sevasemten Results Morning Movers: Shell ticks higher after denying interest in BP deal Edgewise update in line with expectations, says Leerink Truist sees 'slight weakness' for Edgewise Therapeutics on regulatory feedback Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
03-06-2025
- Business
- Associated Press
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
BOULDER, Colo., June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: or follow us on LinkedIn, X , Facebook and Instagram. View original content to download multimedia: SOURCE Edgewise Therapeutics
Yahoo
05-05-2025
- Business
- Yahoo
Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
We recently published a list of . In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps. She also discussed the outlook for the category, saying that the earnings backdrop is essential. When we look back a year ago, investors were excited about small caps, as the earnings were recovering and the market was coming out of the 2023 earnings recession. Everyone expected that these stocks would see double-digit earnings growth by mid-last year, outpacing large caps. That got pushed out for over a year, and now the sector has sold off a lot. While we have gotten some potential good news on tariffs, there is still a lot of uncertainty, and we are in a backdrop where earnings revisions have still been negative. She opined that she would feel more comfortable if we were in a backdrop where there was confidence in earnings recovery because last earnings season, the commentary was a lot more negative from small-cap companies than large-cap companies. So far, this earnings season is still early for small caps, but guidance in both large and small has been weak. READ ALSO: and . Hall said that the sector would see a much better picture if earnings revisions turned around with higher confidence, and not only the tariffs were better than expected but also the economic backdrop was better. However, we are also in a place where economists think the Fed will stay on hold this year, and the Russell has been very sensitive to Fed expectations. Her outlook for small caps thus points towards a more credit-sensitive environment highly tethered to Fed expectations, with no anticipation of a rate cut this year. She also highlighted that looking at corporate commentary as small-cap reporting kicks off is important. Not all small caps are created equal, even when some people consider them to be so. Hall opined that this is definitely a year where you want to be selective in small caps, focusing on stocks with strong margins amid tariff uncertainty. She favored high-quality domestic stocks, steering clear of tariff and refinancing risks and focusing on stocks with positive revisions in this broad backdrop of negative revisions. There are groups of stocks that are more sensitive to tariffs, just as there are groups that are more global and domestic. Similarly, some groups are more levered with higher refinancing risks within small caps if the rate stays higher and credit spreads stay elevated. Therefore, she reasoned that she would stick with higher-quality stocks that are more profitable and have strong operating margins. Stocks with these characteristics have been some of the top performers within the industry amid tariff risks. From a sector perspective, if investors want to be more defensive, utilities screen well across the work, both in small and large caps. There will thus be opportunities in the segment, according to Hall, but one needs to be selective. She also expressed positive sentiments for mid-caps, which have been one of the best performers in the sector this year. They have seen much better revision trends, cleaner balance sheets, and fewer risks from potential earnings hits from tariffs than small caps because the latter have thinner margins and could see a greater hit. We sifted through stock screeners, financial media reports, and ETFs to compile a list of 30 small cap stocks and chose the top 11 with the biggest analyst upside potential as of May 2, 2025. We also included the number of hedge fund holders as of Q4 2024, which we sourced from Insider Monkey's database. The list is presented in ascending order of stocks' upside potential. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A scientist in a lab coat using a microscope to study a cultured biopharmaceutical product. Market Cap: $1.75 billion Analyst Upside: 189.63% Number of Hedge Fund Holders: 49 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company that develops, discovers, and commercializes innovative treatments for serious, rare muscle disorders with considerable unmet medical needs and severe cardiac conditions. Its lead product candidate is sevasemten (EDG-5506), an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. The company ranks seventh on our list of the top small-cap stocks to invest in with the biggest upside potential. Guggenheim analyst Debjit Chattopadhyay initiated coverage of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) with a Buy rating on April 30, setting a $41 price target. The analyst told investors in a research note that the company has two small molecules in mid to late-stage clinical development: sevasemten for Duchenne muscular dystrophy and EGD-7500 for obstructive and non-obstructive hypertrophic cardiomyopathy. According to the analyst, the company's current $1 billion enterprise value 'offers a compelling entry point,' with multiple readouts over the coming 12 months and cash into 2028. Guggenheim also initiated coverage of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) with a Buy rating on the same day, setting a $41 price target. Overall, EWTX ranks 7th on our list of top small cap stocks to buy with biggest upside potential. While we acknowledge the potential for EWTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than EWTX but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
